Log in

NASDAQ:SGENSeattle Genetics Stock Price, Forecast & News

$150.43
-4.62 (-2.98 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$148.91
Now: $150.43
$155.87
50-Day Range
$123.79
MA: $150.61
$164.64
52-Week Range
$63.02
Now: $150.43
$168.10
Volume1.37 million shs
Average Volume1.25 million shs
Market Capitalization$26.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Read More
Seattle Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share

Profitability

Net Income$-158,650,000.00

Miscellaneous

Employees1,605
Market Cap$26.04 billion
Next Earnings Date7/21/2020 (Estimated)
OptionableOptionable

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

How has Seattle Genetics' stock been impacted by COVID-19 (Coronavirus)?

Seattle Genetics' stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SGEN stock has increased by 43.9% and is now trading at $150.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Seattle Genetics?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 7 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seattle Genetics.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, July 21st 2020. View our earnings forecast for Seattle Genetics.

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) issued its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.98) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.17. The biotechnology company earned $234.51 million during the quarter, compared to analysts' expectations of $207.59 million. Seattle Genetics had a negative return on equity of 16.51% and a negative net margin of 32.81%. The business's revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) earnings per share. View Seattle Genetics' earnings history.

What guidance has Seattle Genetics issued on next quarter's earnings?

Seattle Genetics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $810-865 million, compared to the consensus revenue estimate of $965.65 million.

What price target have analysts set for SGEN?

21 brokerages have issued 12-month price targets for Seattle Genetics' stock. Their forecasts range from $95.00 to $185.00. On average, they anticipate Seattle Genetics' share price to reach $143.06 in the next twelve months. This suggests that the stock has a possible downside of 4.9%. View analysts' price targets for Seattle Genetics.

Has Seattle Genetics been receiving favorable news coverage?

News coverage about SGEN stock has been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seattle Genetics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutSeattle Genetics.

Who are some of Seattle Genetics' key competitors?

What other stocks do shareholders of Seattle Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Immunomedics (IMMU), Starbucks (SBUX), Micron Technology (MU), Johnson & Johnson (JNJ), Netflix (NFLX) and salesforce.com (CRM).

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
  • Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seattle Genetics' major shareholders?

Seattle Genetics' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital International Investors (10.67%), BlackRock Inc. (6.40%), Wellington Management Group LLP (4.66%), Primecap Management Co. CA (4.32%), Baillie Gifford & Co. (2.47%) and State Street Corp (1.87%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, Darren S Cline, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View institutional ownership trends for Seattle Genetics.

Which institutional investors are selling Seattle Genetics stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Wellington Management Group LLP, Manning & Napier Group LLC, Frontier Capital Management Co. LLC, Blair William & Co. IL, Federated Hermes Inc., Capital Bank & Trust Co, and APG Asset Management N.V.. Company insiders that have sold Seattle Genetics company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, and Vaughn B Himes. View insider buying and selling activity for Seattle Genetics.

Which institutional investors are buying Seattle Genetics stock?

SGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Samlyn Capital LLC, Capital World Investors, Legal & General Group Plc, 1832 Asset Management L.P., 1832 Asset Management L.P., and Morgan Stanley. View insider buying and selling activity for Seattle Genetics.

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $150.43.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $26.04 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seattle Genetics employs 1,605 workers across the globe.

What is Seattle Genetics' official website?

The official website for Seattle Genetics is www.seattlegenetics.com.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.